Spyre Therapeutics, Inc. (NASDAQ:SYRE) has 151 institutional investors that have filed 13F reports for the period ending December 2025.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Mar, 2026 | 11,781,024 | 142,205 | 1.22% | $594,234,851.00 |
| FMR LLC | 31 Mar, 2026 | 11,638,819 | 2,578,675 | 28.46% | $381,287,711.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 5,522,101 | 1,539,357 | 38.65% | $180,904,030.00 |
| BlackRock, Inc. | 31 Mar, 2026 | 5,521,221 | -880 | -0.02% | $278,490,385.00 |
| RTW INVESTMENTS, LP | 31 Mar, 2026 | 4,171,996 | 0 | 0.00% | $210,435,478.00 |
| RTW INVESTMENTS, LP | 31 Mar, 2026 | 4,171,996 | 550,000 | 15.18% | $136,674,589.00 |
| VANGUARD GROUP INC | 31 Mar, 2026 | 4,035,074 | 984,344 | 32.27% | $132,189,024.00 |
| Fairmount Funds Management LLC | 31 Mar, 2026 | 4,018,101 | 0 | 0.00% | $202,673,014.00 |
| Fairmount Funds Management LLC | 31 Mar, 2026 | 4,018,101 | 0 | 0.00% | $131,632,989.00 |
| PERCEPTIVE ADVISORS LLC | 31 Mar, 2026 | 3,783,225 | 714,000 | 23.26% | $190,825,869.00 |
| VR Adviser, LLC | 31 Mar, 2026 | 3,685,448 | 1,000,000 | 37.24% | $120,735,276.00 |
| Venrock Adviser, LLC | 31 Mar, 2026 | 3,685,448 | 0 | 0.00% | $185,893,997.00 |
| Capital International Investors | 31 Mar, 2026 | 3,492,541 | 1,100,000 | 45.98% | $114,415,643.00 |
| Janus Henderson Group Plc | 31 Mar, 2026 | 3,312,328 | 1,483,319 | 81.10% | $167,173,194.00 |
| PERCEPTIVE ADVISORS LLC | 31 Mar, 2026 | 3,069,225 | 1,839,780 | 149.64% | $100,547,811.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 3,057,401 | 3,057,401 | 0.00% | $154,215,306.00 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 2,882,420 | 822,045 | 39.90% | $94,428,079.00 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 31 Mar, 2026 | 2,790,785 | -91,635 | -3.18% | $140,767,195.00 |
| State Street Corp | 31 Mar, 2026 | 2,607,031 | 344,192 | 15.21% | $131,498,644.00 |
| Commodore Capital LP | 31 Mar, 2026 | 2,388,245 | 400,161 | 20.13% | $78,238,906.00 |